Open Access. Powered by Scholars. Published by Universities.®
Endocrinology, Diabetes, and Metabolism Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Sciences (41)
- Life Sciences (27)
- Diseases (26)
- Biochemical Phenomena, Metabolism, and Nutrition (22)
- Endocrine System Diseases (21)
-
- Dietetics and Clinical Nutrition (20)
- Nutrition (19)
- Public Health (17)
- Internal Medicine (9)
- Cardiology (7)
- Cardiovascular Diseases (6)
- Pediatrics (6)
- Geriatrics (5)
- Bioinformatics (4)
- Biomedical Informatics (4)
- Community Health and Preventive Medicine (4)
- Wounds and Injuries (4)
- Critical Care (3)
- Physical Sciences and Mathematics (3)
- Podiatry (3)
- Biochemistry, Biophysics, and Structural Biology (2)
- COVID-19 (2)
- Data Science (2)
- Epidemiology (2)
- Genetic Phenomena (2)
- Medical Genetics (2)
- Nephrology (2)
- Institution
- Publication Year
- Publication
-
- Children’s Nutrition Research Center Staff Publications (17)
- Faculty, Staff and Student Publications (14)
- Faculty, Staff and Students Publications (14)
- Center on Aging Staff Publications (4)
- Department of Medicine Faculty Papers (2)
-
- The Texas Heart Institute Journal (2)
- Articles, Abstracts, and Reports (1)
- Center for Medical Ethics and Health Policy Staff Publications (1)
- Department of Otolaryngology - Head and Neck Surgery Faculty Papers (1)
- Division of Endocrinology, Diabetes and Metabolic Diseases Faculty Papers (1)
- GW Biostatistics Center (1)
- Hospital Medicine (1)
- Journal Articles: Diabetes, Endocrinology & Metabolism (1)
- NYMC Faculty Publications (1)
- Pharmacy and Wellness Review (1)
- Publication Type
Articles 61 - 62 of 62
Full-Text Articles in Endocrinology, Diabetes, and Metabolism
After Avandia: The Use Of Antidiabetic Drugs In Patients With Heart Failure, Khaled I Khalaf, Heinrich Taegtmeyer
After Avandia: The Use Of Antidiabetic Drugs In Patients With Heart Failure, Khaled I Khalaf, Heinrich Taegtmeyer
The Texas Heart Institute Journal
Managing diabetes mellitus is an ongoing concern, especially in the presence of heart failure. Recent reports have drawn attention to adverse cardiovascular events associated with the use of thiazolidinediones, including rosiglitazone (Avandia). In 2011, the U.S. Food and Drug Administration implemented a stringent “restricted access program” for the prescription of Avandia. Other studies, which have revealed increased mortality rates in association with tight glycemic control, raise serious concerns about managing diabetes in heart-failure patients.
Herein, we provide a perspective on the management of noninsulin-dependent diabetes in patients with heart failure. We point out that thiazolidinediones exert their major effects through …
Reduction In The Incidence Of Type 2 Diabetes With Lifestyle Intervention Or Metformin., William C. Knowler, Elizabeth Barrett-Connor, Sarah E. Fowler, Richard F. Hamman, John M. Lachin, Elizabeth A. Walker, David M. Nathan, P. G. Watson, J. T. Mendoza, K. A. Smith, J. Caro, B. Goldstein, C. Lark, L. Menefee, L. Murphy, C. Pepe, J. M. Spandorfer
Reduction In The Incidence Of Type 2 Diabetes With Lifestyle Intervention Or Metformin., William C. Knowler, Elizabeth Barrett-Connor, Sarah E. Fowler, Richard F. Hamman, John M. Lachin, Elizabeth A. Walker, David M. Nathan, P. G. Watson, J. T. Mendoza, K. A. Smith, J. Caro, B. Goldstein, C. Lark, L. Menefee, L. Murphy, C. Pepe, J. M. Spandorfer
Department of Medicine Faculty Papers
BACKGROUND: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes.
METHODS: We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least …